nach oben

memo - Magazine of European Medical Oncology

Erschienen in:

01.06.2021 | editorial

Immunotherapy revisited

verfasst von: Assoc. Prof. PD Dr. Thorsten Füreder

Erschienen in: memo - Magazine of European Medical Oncology | Ausgabe 2/2021

Einloggen, um Zugang zu erhalten

Excerpt

Immunotherapy has revolutionized cancer treatment during the last few years. Impressive long-term survival rates (beyond 5 years) even in deadly diseases such as metastatic lung cancer or malignant melanoma were achieved by checkpoint inhibitor (CPI) therapy. …

Nächster Artikel Treatment approaches towards physical activity – malnutrition – cognitive impairment

Zila N, Hoeller C, Paulitschke V. Novel immune checkpoints beyond PD‑1 in advanced melanoma. memo. 2021;14(2). https://doi.org/10.1007/s12254-021-00699-0.CrossRef

Umut Ö, Gottschlich A, Endres S, Kobold S. CAR T cell therapy in solid tumors: a short review. memo. 2021;14(2). https://doi.org/10.1007/s12254-021-00703-7.CrossRef

Heller G. DNA methylation as predictive marker of response to immunotherapy?. memo. 2021;14(2). https://doi.org/10.1007/s12254-021-00696-3.

Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Five-year survival with combined nivolumab and Ipilimumab in advanced melanoma. N Engl J Med. 2019;381:1535–46.CrossRef

Jacobson C, Locke FL, Ghobadi A, et al Long-Term Survival and Gradual Recovery of B Cells in Patients with Refractory Large B Cell Lymphoma Treated with Axicabtagene Ciloleucel (Axi-Cel). Blood 2020; 136 (Supplement 1): 40–42. https://doi.org/10.1182/blood-2020-134362.

Aguiar PN Jr., Santoro IL, Tadokoro H, et al. The role of PD-L1 expression as a predictive biomarker in advanced non-small-cell lung cancer: a network meta-analysis. Immunotherapy. 2016;8:479–88.CrossRef

Titel: Immunotherapy revisited
verfasst von: Assoc. Prof. PD Dr. Thorsten Füreder
Publikationsdatum: 01.06.2021
Verlag: Springer Vienna
Erschienen in: memo - Magazine of European Medical Oncology / Ausgabe 2/2021
Print ISSN: 1865-5041
Elektronische ISSN: 1865-5076
DOI: https://doi.org/10.1007/s12254-021-00711-7

Springer Medizin Österreich

Excerpt

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2021

European Society for Medical Oncology 2020

Treatment approaches towards physical activity – malnutrition – cognitive impairment

ESMO 2020 update: Pancreatic cancer

ESMO 2020: highlights in breast cancer

Leptomeningeal metastases from solid tumours

DNA methylation as predictive marker of response to immunotherapy?